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Pulmonary arteriovenous malformation (PAVM) is a se-rious complication after cavopulmonary shunt. Althoughthe etiology remains unclear, substances in the hepaticvenous effluent are thought to play a crucial role in the
formation of PAVM,1 and reports have shown regression of
PAVM after surgical inclusion of hepatic venous flow to the
lung.2,3 Recently, neurohormonal abnormality was reported after
cavopulmonary shunt.4 We measured neurohormones in 5 patients
after cavopulmonary shunt and obtained evidence that angiotensin
has some relation to the development of PAVM.
Clinical Summaries
A 7-year-old girl (patient 1), 1 year after Fontan completion,
was admitted because of dyspnea on effort. Cardiac catheter-
ization demonstrated that only the right lung received the he-
patic venous flow, and diffuse PAVM existed in the left lung.
An operation was performed to redirect hepatic venous flow to
both lungs. Cardiac catheterization demonstrated complete re-
gression of PAVM at 2 postoperative months and trivial PAVM
in the left lung at 1 postoperative year. In this period, plasma
renin, angiotensin I (AT-I), angiotensin II (AT-II), aldosterone,
somatostatin, glucagon, vasoactive intestinal peptide, and atrial
natriuretic peptide were measured in blood samples from the
superior vena cava, the hepatic vein, the right and left pulmo-
nary arteries, and the aorta at 4 intervals. Consonant with the
development and regression of PAVM, AT-I and AT-II levels
were increased and decreased in all regions (Table 1). Renin
levels remained high even after the operation. Other parameters
were within their reference ranges.
As a control group, 4 patients without PAVM after the Fontan
operation (patients 2-5) were examined. Two (patients 2 and 3) had
elevated plasma concentrations of AT-I, but the other parameters
remained within normal limits.
Discussion
Neurohormonal activation during the course of several years
after cavopulmonary shunt has been demonstrated.4 In our
study, similarly, 3 of 5 patients showed elevated AT-I (Figure
1, A and B). Moreover, in 1 of our patients AT-I and AT-II
increased consonant with the development of PAVM and de-
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Figure 1. Plasma angiotensin levels after cavopulmonary
shunt. A and B, Angiotensin levels in superior vena cava blood
(A) and hepatic venous blood (B) in each patient at various
times after Fontan operation. C and D, Angiotensin levels in
patient 1. Values are plotted according to intraoperative (C)
and postoperative (D) hepatic venous flows. SVC, Superior
vena cava; Pt, patient; lt, left; rt, right; HV, hepatic vein; PA,
pulmonary artery; Ao, aorta.
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creased consonant with its regression. To the best of our knowl-
edge, this is the first clinical evidence that angiotensin is
elevated in relation to the development of PAVM. Experimen-
tally, Malhotra and colleagues5 demonstrated elevation in the
expression of AT-II receptors in an ovine model of PAVM.
These data suggest that activation of the renin-angiotensin
system plays some role in the development of PAVM after
cavopulmonary shunt.
In patient 1, left PAVM developed as a result of the lack of
hepatic venous flow. In this period, plasma AT-I and AT-II
levels showed differences between the right and the left pul-
monary arteries. We plotted these values according to the
intraoperative and postoperative hepatic venous flows (Figure
1, C and D ), demonstrating that AT-I and AT-II were activated
mainly in the right lung preoperatively. After redirection of
hepatic venous flow, both lungs received equal hepatic venous
flow and activated AT-I and AT-II. Abnormal circulation in
which hepatic venous effluent bypasses one lung may induce
abnormal metabolisms of neurohormones such as angiotensin,
resulting in abnormal vascular changes after cavopulmonary
shunt. It is still unclear whether this abnormal activation of
angiotensin during the development of PAVM is primary or
secondary. Further investigation, including measurement of an-
giotensinogen, is needed to clarify this phenomenon.
Conclusion
We demonstrated elevation of angiotensin during the develop-
ment of PAVM. Circulation in which hepatic venous flow
bypasses the lung seems to induce abnormal metabolism of the
rennin-angiotensin system and to play some role in the development
of PAVM.
TABLE 1. Neurohormonal activity after cavopulmonary shunt
Patient 1 Patient 2
(3 PO y)
Patient 3
(7 PO y)
Patient 4
(10 PO y)
Patient 5
(17 PO y)Preoperative Intraoperative 2 PO mo 1 PO y
Diagnosis SA, SV, CAVV, CoA, azygos continuation, left isomerism SA, SV MA SA, SV TA
Age (y) 7 8 8 9 13 44 22 22
PAVM Develop (lt) Develop (lt) Regress Trivial (lt) None None None None
Renin (U/mL, normal 64)
SVC 93 170 130 290 33 35 17 48
HV 49 120 170 210 34 22 12 38
RPA 77 170 160 280 45 37 15 49
LPA 88 180 160 430 35 22 14 49
Aorta – 180 190 370 – 37 18 50
AT-I (pg/mL, normal 110)
SVC 660 1200 330 700 300 440 39 67
HV 330 960 300 610 310 210 30 41
RPA 520 1700 490 560 350 480 30 62
LPA 670 1000 310 690 510 230 34 56
Aorta – 1200 480 590 – 370 47 53
AT-II (pg/mL, normal 22)
SVC 54 82 36 96 17 16 9 16
HV 13 15 8 20 12 7 3 5
RPA 32 130 17 46 17 11 4 13
LPA 36 61 23 110 12 5 10 10
Aorta – 120 42 63 – 8 4 8
Aldosterone (pg/mL, normal 35-240)
SVC 180 150 290 390 120 37 91 68
HV 200 180 84 75 76 17 39 41
RPA 290 180 220 330 110 43 110 66
LPA 220 160 160 310 120 19 72 67
Aorta – 140 300 300 – 36 75 71
Somatostatin (pg/mL, normal 1-12)
SVC 10 5.9 30 8.9 17 9.6 1.8 6.6
HV 28 7.6 9.8 11 26 3.9 10 11
RPA 15 1 4.4 5.1 14 8 3.1 9.5
LPA 10 7 9.8 5.5 23 12 6.6 2.7
Aorta – 1 4.5 3.5 – 3.5 9 9
PO, Postoperative; SA, single atrium; SV, single ventricle; CAVV, common atrioventricular valve; CoA, coarctation of the aorta; lt, left; MA, mitral atresia;
TA, tricuspid atresia; SVC, superior vena cava; HV, hepatic vein; RPA, right pulmonary artery; LPA, left pulmonary artery.
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